摘要:2026年上半年,国内CXO行业整体迎来复苏窗口,头部企业业绩回暖验证赛道基本面韧性,老牌CDMO企业九洲药业却迎来多年少见的营收、利润同步回调。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.